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Malaria caused by Plasmodium falciparum kills nearly one million
children each year and imposes crippling economic burdens on
families and nations worldwide. No licensed vaccine exists, but
infection can be prevented by antibodies against the circumspor-
ozoite protein (CSP), the major surface protein of sporozoites, the
form of the parasite injected by mosquitoes. We have used vec-
tored immunoprophylaxis (VIP), an adeno-associated virus-based
technology, to introduce preformed antibody genes encoding anti-
P. falciparum CSP mAb into mice. VIP vector-transduced mice ex-
hibited long-lived mAb expression at up to 1,200 μg/mL in serum,
and up to 70% were protected from both i.v. and mosquito bite
challenge with transgenic Plasmodium berghei rodent sporozoites
that incorporate the P. falciparum target of the mAb in their CSP.
Serum antibody levels and protection from mosquito bite challenge
were dependent on the dose of the VIP vector. All individual mice
expressing CSP-specific mAb 2A10 at 1 mg/mL or more were com-
pletely protected, suggesting that in this model system, exceeding
that threshold results in consistent sterile protection. Our results dem-
onstrate the potential of VIP as a path toward the elusive goal of
immunization against malaria.
AAV | vectored gene delivery
Among infectious diseases, malaria ranks fourth as a cause ofdeath. In Africa in 2012, 500,000–800,000 deaths, mostly
among children under 5 y of age, resulted from ∼200 million
clinical cases of malaria caused by Plasmodium falciparum, the
parasite species responsible for most malaria mortality (1). In
addition to its direct effect on health, malaria imposes severe
economic burdens. These include crippling treatment costs at the
level of individual families and a significant contribution to low
national incomes and reduced overall rates of economic growth in
nations worldwide (2, 3). The human and economic burdens im-
posed by malaria make malaria reduction a critical global priority.
Traditional approaches to malaria control such as antimalarial
drug treatment, mosquito control by habitat modification and
insecticide use, and reduction of exposure to infected mosquitoes
have had substantial success in reducing malaria incidence and
malaria-specific mortality rates (4). However, these achieve-
ments may be difficult to sustain in the face of growing drug
resistance among parasites, insecticide resistance in vector pop-
ulations, and the reduced funding for malaria control anticipated
by the World Health Organization for the near future (4). If
continued progress against malaria is to be made, it is essential
that new approaches for malaria prevention be added to currently
available tools.
Sporozoites are the infectious form of the malaria parasite
injected by Anophelesmosquitoes. It has been known for decades
that immunization of animals or humans with radiation-attenu-
ated sporozoites can elicit sterilizing immunity to malaria, pre-
venting infection, pathogenesis, and transmission (5–8). The
predominant antibody response to immunization by irradiated
sporozoites is to the circumsporozoite protein (CSP), which
coats the sporozoite surface (9, 10). In in vivo and in vitro models
of P. falciparum sporozoite infection, infection can be blocked
completely by antibody to the immunodominant epitope of CSP,
a tetrapeptide [asn-ala-asn-pro (NANP)] found in 30 or
more tandemly repeated copies in the central region of the
protein (11–13). The NANP repeat is stringently conserved in
P. falciparum isolates from diverse geographical locations (14)
and thus represents a potentially universal target for P. falciparum
immunity. The most advanced malaria infection-blocking vaccine
candidate, RTS,S, is comprised of hepatitis B virus-like particles
that display a carboxyl-terminal segment of P. falciparum CSP,
including part of the central NANP repeat region. Immunization
with RTS,S reduces incidence of clinical malaria by 40–70% in
children, but levels of protection wane with time (15–18).
Vectored immunoprophylaxis (VIP) provides an alternative to
conventional immunization as a route to protective antibody
expression (19–21). VIP employs optimized adeno-associated
virus (AAV) based vectors to deliver genes encoding mAb with
previously characterized specificities to animals. Intramuscular
injection of VIP vectors in mice and macaques elicits long-lived
antibody or antibody-related immunoadhesin production at levels
sufficient to protect against HIV, simian immunodeficiency virus,
and influenza A virus infection (19–22). Here we report that in
mice, VIP-directed production of sporozoite-neutralizing mAb
against the P. falciparum CSP central repeat can confer sterile
immunity to infection by a transgenic strain of the rodent parasite
Plasmodium berghei whose CSP contains the P. falciparum CSP
central repeat [Pb/Pf (12)].
Results
Construction and Characterization of VIP Vectors Expressing mAb
Against P. falciparum CSP. The VIP system (20) permits con-
struction of vectors that express human IgG (hIgG) antibodies
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that bear the variable region sequences, and thus possess the
binding specificities, of previously characterized mAb. Briefly,
synthetic DNA segments encoding the variable regions of the
mAb are inserted into an optimized hIgG gene in a modular
AAV2-derived plasmid backbone that includes a muscle-opti-
mized promoter, a splice donor and splice acceptor pair, a poly-
adenylation signal, and a posttranscriptional enhancer that
together ensure efficient transgene expression. The plasmid also
contains AAV2 inverted terminal repeats to permit vector ge-
nome encapsidation. AAV particles containing the transgene are
produced by transfection of cells in tissue culture with the VIP
vector plasmid and helper plasmids that supply required ade-
novirus products, AAV rep and AAV8 capsid protein. In-
tramuscular injection of the VIP virions results in production of
the hIgG transgene product by transduced muscle cells in vivo.
To explore the potential of VIP against P. falciparum, VIP vec-
tors encoding hIgG specific for the P. falciparum CSP central
repeat were constructed by inserting the variable regions of
mouse mAb 2A10 and 2C11 (23, 24) into the hIgG framework of
the VIP expression plasmid (20). The 2A10 and 2C11 mAb each
recognize three or more tandem repetitions of the CSP NANP
central repeat epitope. Both inhibit hepatic cell invasion by
P. falciparum sporozoites in vitro, and passively transferred 2A10
prevents infection of mice by transgenic Pb/Pf parasites. The vec-
tors, 2A10-AAV and 2C11-AAV, expressed hIgG in vitro at levels
comparable to those directed by a VIP vector that encodes the
HIV mAb b12 and protects humanized mice against HIV infection
(b12-AAV; Fig. S1) (20).
C57BL/6 mice were injected in the cranial thigh muscle with
1 × 1011 genome copies (GC) of 2A10-AAV, 2C11-AAV, b12-
AAV, or with buffer. Within 1 wk, AAV-transduced mice
expressed hIgG at 50–500 μg/mL in serum (Fig. 1A). Expression
increased until ∼4 wk posttransduction, reaching 1,000 μg/mL in
two mice, and was sustained through 8 wk when transduced mice
were challenged. The 2A10-AAV and 2C11-AAV–transduced
mice expressed antibodies that bound recombinant CSP (Fig. 1B)
and that recognized whole P. falciparum sporozoites (Fig. 1C). Sera
from b12-AAV–transduced mice recognized neither recombinant
CSP nor sporozoites.
VIP has induced extended mAb production in mice (19, 20). To
determine the longevity of the expression of malaria mAb, hIgG
in additional 2A10-AAV, 2C11-AAV, and b12-AAV–transduced
mice were monitored over several months. Serum antibody con-
centrations reached a plateau 4–8 wk posttransduction and were
maintained at that level for the duration of the study (52 wk;
Fig. S2).
i.v. Challenge of AAV-Transduced Mice with Pb/Pf Sporozoites. To
determine whether VIP-directed mAb production was protective
against malaria infection, transduced mice were challenged with
Pb/Pf sporozoites either injected i.v. or introduced by the bites of
infected mosquitoes. For i.v. challenge, 1 × 104 Pb/Pf sporozoites
isolated from infected Anopheles stephensi mosquitoes were
injected into the tail vein of mice 8 wk posttransduction. Chal-
lenged mice were killed 40–42 h postchallenge, when infectious
sporozoites would have successfully invaded and replicated in liver
cells. RNA was extracted from whole liver homogenates, and
parasites in the liver (liver parasite burden) were quantified by
quantitative PCR (qPCR) measurement of P. berghei 18S rRNA
(25). The 2A10-AAV–transduced mice had a statistically signifi-
cant reduction in liver parasite burden compared with b12-AAV
mice (Fig. 2), and 7 of 10 2A10-AAV–transduced mice had par-
asite 18S rRNA levels that were at the background levels seen in
unchallenged control mice. Both 2A10 and 2C11-transduced mice
displayed a statistically significant decrease in parasite rRNA
levels in a second, independent challenge with a different number
(2 × 104) of Pb/Pf sporozoites (Fig. S3).
Challenge of VIP-Transduced Mice with Pb/Pf Sporozoites by Infected
Mosquito Bite.Mosquito bites are the natural route of exposure to
malaria. Therefore, groups of transduced mice were challenged
by exposure to Pb/Pf-infected mosquitoes. Mice immunized with
three i.v. injections of radiation-attenuated Pb/Pf sporozoites
were included as a positive protection control. Starting at 4 d
Fig. 1. VIP vectors drive expression of human anti-CSP antibodies in mice. Quantification of hIgG (A) and anti-CSP antibodies (B) in serum taken from female C57BL/
6 mice at indicated times after intramuscular injection with 1011 GC of vectors 2A10-AAV or 2C11-AAV encoding anti-P. falciparum CSP mAb, b12-AAV encoding
anti-HIV glycoprotein120 mAb b12, or vehicle alone (n = 10 per group). Mice transduced with vehicle alone had hIgG below the limit of detection. Means and SEs
are shown for the 10 mice in each group. (C) Immunofluorescence micrographs of P. falciparum sporozoites incubated with pooled sera from mice transduced with
the indicated vector and stained with anti-human IgG FITC conjugates. The phase contrast images cover the same fields and show the location of sporozoites.









postchallenge, mice were checked daily by blood smear to
determine when blood-stage parasites (parasitemia) appeared.
Parasitemia indicates that sporozoites escaped the anti-CSP
mAb and successfully invaded the liver, where they replicate and
differentiate to produce blood-stage infection. In a bite chal-
lenge, freedom from parasitemia for 14 d indicates complete
protection. Sixty percent of 2A10- and 30% of 2C11-AAV–
transduced mice did not develop parasitemia by 14 d post-
exposure, demonstrating sterile protection (Fig. 3A). Both groups
of CSP mAb-expressing mice also displayed significant delays
in time to parasitemia compared with the b12-AAV control group
by Kaplan–Meier survival analysis. All mice vaccinated with irra-
diated sporozoites were protected from challenge (Fig. 3A), and
all mock-transduced mice and those receiving b12-AAV exhibited
parasitemia by day 8. To confirm that the sterile protection ob-
served was not a consequence of poor feeding by mosquitoes on
transduced mice, the number of mosquitoes that took a blood
meal from each mouse was determined. Protected and parasitemic
mice fed similar average numbers of mosquitoes (Fig. 3B) and
consequently received similar sporozoite inocula.
Protection from HIV and influenza infection is correlated with
serum antibody levels (19, 20). Therefore, we compared the
hIgG levels in 2A10-AAV and 2C11-AAV–transduced mice
immediately before challenge with time to parasitemia in bite-
challenged groups (Fig. 3 C and D and Fig. S4). A statistically
significant correlation was seen between antibody concentration
and time to parasitemia for 2A10-AAV mice (P = 0.0105, Fig.
3C). No significant correlation was seen in bite-challenged 2C11-
AAV mice (Fig. 3D).
Dose–Response in VIP-Transduced Mice. To examine the effects of
vector dose on mAb production and the effects of mAb con-
centration on protection systematically, groups of 10 mice were
transduced with doses of 2A10-AAV ranging from 3 × 109 GC
to 1011 GC, or with 1011 GC of b12-AAV. hIgG expression
showed vector dose dependence at each time point examined (Fig.
4A). Mice were challenged by infected mosquito bite at 11 wk
posttransduction and exhibited dose-dependent protection: 70%
of mice that received the highest AAV dose (1 × 1011 GC) were
protected, as were 40% of mice that received 3 × 1010 GC and
10% of mice that received 1 × 1010 GC (Fig. 4B). All mice trans-
duced with 3 × 109 GC were parasitemic by day 7, and all b12-AAV
mice were parasitemic by day 6. The number of mosquitoes taking
a blood meal did not impact development of parasitemia (Fig. 4C),
but the correlation between 2A10 antibody concentration and day
to parasitemia was highly statistically significant (P = 0.0013,
Fig. 4D). Notably, all six mice that had greater than 1,000 μg/mL
of mAb 2A10 were completely protected from sporozoite cha-
llenge. Thus, high mAb concentration contributes to protective
efficacy, and in this system, a 2A10 mAb level of 1,000 μg/mL
provides reliable protection against sporozoite infection.
Discussion
These data show that in a murine model of human P. falciparum
infection, a single intramuscular injection of a VIP vector encod-
ing a mAb that neutralizes malaria sporozoites can confer pro-
tection from mosquito-borne malaria infection. In all experiments
combined, sterile protection against mosquito bite challenge was
achieved in every 2A10-AAV–transduced mouse with a hIgG se-
rum concentration of 1,000 μg/mL or greater (9 out of 9), and
in 65% (13 of 20) of mice that received the “standard” vector dose
of 1011 GC, regardless of hIgG concentration. For mAb 2C11,
serum mAb levels were generally lower than for 2A10, and no
mouse achieved a mAb concentration of 1,000 μg/mL Nevertheless,
Fig. 2. VIP-encoded CSP antibodies reduce liver parasite burden. The mice
shown in Fig. 1 were challenged i.v. with 1 × 104 Pb/Pf sporozoites isolated
from infected A. stephensi mosquitoes 8 wk posttransduction with b12-AAV,
2A10-AAV, 2C11-AAV, or mock transduction. Liver parasite burdens were
assessed 40–42 h postchallenge by qRT-PCR measurement of P. berghei 18S
rRNA in liver homogenates. Plotted are values for individual mice (n = 5 or 10)
and the geometric mean of each group. Unchallenged mice did not receive
sporozoites (n = 4). Asterisks indicate mean rRNA levels significantly different
(P < 0.001) from b12 control mice by two-tailed t test (n = 10). Arrows indicate
mice with a detectable anti-human Fc humoral immune response.
Fig. 3. VIP can provide sterile protection in mice challenged by infected
mosquito bite. (A) Mice transduced with 1011 GC of 2A10-, 2C11-, or b12-
AAV, or mock-transduced (n = 10 per group) were challenged 11 wk post-
transduction bymosquito bites from 10 Pb/Pf infectedA. stephensimosquitoes
for 5 min. An additional group of mice immunized by three injections with
1 × 105 to 1.5 × 105 irradiated Pb/Pf sporozoites (Irr. spz.) were also chal-
lenged (n = 5). Mice were microscopically assessed for blood-stage parasites
by blood smear daily, starting at day 4 postchallenge through day 14, when
nonparasitemic mice were considered sterilely protected. Asterisks denote
a statistically significant difference in survival compared with b12-transduced
control mice. *P < 0.05, ***P < 0.005 by Kaplan–Meier logrank test.
(B) Number of mosquitoes taking a blood meal from mice that eventually
became infected (NP) or from protected mice (P). No significant differences
were observed in number of bites per mouse (P = 0.6095 for 2A10; P = 0.3883
for 2C11-AAV by a Mann–Whitney test). The number of mosquitoes that fed
on each mouse was determined by the examination of mosquitoes in each
challenge cup for the presence of blood in the midgut. (C and D) HIgG levels in
individual transduced mice, determined by ELISA immediately before chal-
lenge, plotted against time to the appearance of parasitemia in 2A10- (C) and
2C11-AAV–(D) transduced mice. A linear regression line is shown in C for vi-
sualization of the correlation of IgG concentration with time to parasitemia for
2A10 (r = 0.78 by a two-tailed Spearman test).
12530 | www.pnas.org/cgi/doi/10.1073/pnas.1407362111 Deal et al.
sterile protection was achieved in 3 mice (of 20) inoculated at 1011
GC. The less consistent success of 2C11 in conferring sterile im-
munity might reflect differences in the fine specificities of the 2A10
and 2C11 mAb (26). The mAb levels apparently required for
protection of mice from malaria infection are substantially higher
than those required for HIV and influenza (19–21). This probably
reflects the limited time sporozoites are exposed to antibodies
before liver cell invasion and the capacity of a single unneutralized
sporozoite to initiate a full-blown infection (27–30). The efficacy
of VIP in protecting against HIV varies among vectors that
express different HIV-neutralizing antibodies (20), and surveys
of anti-CSP mAb may reveal antibodies more effective in malaria
VIP. Targeting other sporozoite antigens, either singly or in
combination with CSP, also might provide protection at lower
mAb concentrations. It is unknown what levels of VIP-driven
mAb production might be achieved in humans, what an effective
anti-CSP mAb level might be in humans, or whether mAb other
than those examined here might prove effective at a lower serum
concentration. These questions must all be considered in looking
forward to human trials.
Antigenic diversity presents a major obstacle to vaccine de-
velopment. Many malaria antigens exhibit antigenic diversity, in-
cluding CSP (31). However, the conserved CSP central repeat
epitope recognized by 2A10 and 2C11 is universally present among
P. falciparum isolates (14, 26). Additionally, the NANP epitope is
present in multiple tandem copies in each CSP gene, and multiple
mutations would be required to ablate reactivity with central re-
peat mAb. It therefore seems unlikely that CSP antigenic diversity
or mutational escape will affect the efficacy of immunoprophylaxis
directed against the CSP central repeat. Each Plasmodium species
possesses a CSP with a species-specific central repeat region (32),
and CSP also provides an attractive target for VIP against other
Plasmodium parasites of public health significance.
In macaques, AAV-mediated anti-HIV immunoadhesin pro-
duction and protection can be long-lived [up to 5 y (22)], sug-
gesting use of VIP for vaccine-like immunization against malaria.
In areas where malaria transmission is unstable, VIP might be
used to decrease malaria susceptibility to levels where the dis-
ease can be locally eliminated (33). The anticipated ability of
VIP to confer rapid protection also suggests utility in responding
to introduction or reintroduction of the parasite into parasite-
free regions and in protecting individuals at risk for infection for
shorter periods of time. The roles that VIP might fill in the
campaign against malaria will be defined by the properties and
efficacy of the technology in humans. However, clinical efficacy
of VIP in any of these contexts would be immensely valuable and
could provide an exciting new approach to the urgent goal of
effective malaria control.
Methods
Mice. C57BL/6NCr (C57BL/6) female mice 5–8 wk of age were obtained from
the National Cancer Institute. Animal experiments were conducted in ac-
cordance with the policies and with the approval of the Johns Hopkins
University institutional animal care and use committee.
Construction and Production of VIP Vectors. DNA segments corresponding to
the heavy and light chain variable regions of anti-P. falciparum mAb 2A10
and 2C11 (24) were synthesized (Integrated DNA Technologies) and inserted
into the hIgG1 constant region framework in the VIP expression vector as
previously described (20). VIP vector production, quantitation, and storage
were as previously described (20, 34). Briefly, 293T cells were cotransfected
with the AAV backbone vector, helper plasmid pHELP (Applied Viromics),
and plasmid pAAV2/8 SEED (University of Pennsylvania Vector Core) at a
ratio of 0.25:1:2. Culture supernatants were collected at 36, 48, 72, 96, and
120 h after transfection and pooled. Virus was precipitated by a 40% poly-
ethylene glycol solution. Precipitated virus was banded to equilibrium in
a 1.36 g mL−1 cesium chloride solution in a Sorvall T1270 rotor at 60,000 rpm
for 24 h. Collected fractions exhibiting a refractive index between 1.3755
and 1.3655 were combined and diluted in test formulation buffer 2 (TFB2;
100 mM sodium citrate, 10 mM Tris, pH 8). Virus was concentrated and
washed with TFB2 by centrifugation at 500 g at 4 °C using 100 kDa molecular
weight cutoff centrifugal filters (Millipore). Virus was aliquoted and stored
at −80 °C. Viral genomes were quantified by qPCR.
Vector Administration. Before intramuscular injection, virus was thawed and
diluted to 1 × 1011 GC or the indicated dose with TFB2 in a 50 μL volume.
Virus was administered to mice in a single injection of 50 μL into the cranial
thigh muscle. At various times following vector administration, mice were
bled via the cheek or tail vein.
Quantification of Antibody Production by ELISA. ELISA plates were coated
overnight with 1 μg/well of goat anti-human IgG-Fc antibody (Bethyl) for
total hIgG. Plates were blocked with 1% BSA (Sigma) for 1 h. Samples were
serially diluted in 1% BSA and incubated in coated wells for 1 h, followed by
1 h incubation with horseradish peroxidase (HRP)-conjugated goat anti-
human kappa light chain antibody (Bethyl). Wells were developed using
ABTS Peroxidase Substrate 2-Component System (KPL). A standard curve was
generated using Human Reference Serum (Bethyl) to quantitate total hIgG.
For detection of CSP antibodies, plates were coated with 0.05 μg per well
of recombinant P. falciparum CSP purified from MRA-272 (Malaria Research
and Reference Reagent Resource Center) overnight. All subsequent steps are
described above, except a standard curve was not used. Purified 2A10 was
used as a positive control, and the endpoint ELISA titer was reported as the
reciprocal of the highest dilution at which the optical density was two times
greater than the background. For detection of CSP antibodies in irradiated
sporozoite-immunized mice, an HRP-conjugated anti-mouse IgG (1:5,000
dilution; GE Healthcare) was used as a secondary.
Immunofluorescent Assay. To determine whether transduced mouse serum
recognizes sporozoites, slides (Tekdon, Inc.; Poly-L-Lysine–coated) were
spotted with 10 μL of P. falciparum sporozoites at a concentration of
4–6 × 105 sporozoites per milliliter and air-dried. Slides were blocked for
Fig. 4. Antibody expression and protection from sporozoite challenge is de-
pendent upon vector dose. Mice were injected intramuscularly with 1 × 1011,
3 × 1010, 1 × 1010, or 3 × 109 GC of 2A10-AAV or 1 × 1011 GC of b12-AAV. (A)
Expression of mAb 2A10 and b12 determined by total hIgG ELISA on serum
samples at indicated times. Plot shows the mean and SE for the 10mice in each
group. (B) A Kaplan–Meier survival curve plotting percent of parasite-free mice
over time following challenge with bites from 10 Pb/Pf infected A. stephensi
mosquitoes for 5 min. *P < 0.05, ***P < 0.005 by Kaplan–Meier logrank test.
(C) The number of blood-fed mosquitoes for individual mice that eventually
developed blood-stage parasitemia (NP) or that were protected from chal-
lenge (P). (D) The day to detection of parasitemia for each mouse as a function
of hIgG concentration. Each circle denotes an individual mouse, and a linear
regression is shown for visualization of correlation (r = 0.4424; two-tailed
Spearman test). The vector dose received by individual mice is indicated in D by
the color of the symbol.









1 h with 10 μL of PBS-1% BSA. Serum samples from each mouse per group
were pooled, and 500 ng of hIgG, determined from hIgG ELISA titers, were
diluted in PBS-1% BSA and incubated on slides for 1 h at RT. Slides were
washed in PBS-1% BSA, and 10 μL of fluorescein isothiocyanate (FITC)-
labeled goat anti-monkey IgG (H+L) (KPL) was added for 1 h at RT. Before
visualization, slides were washed with PBS-1% BSA, and coverslips were
mounted with Prolong Gold antifade reagent with DAPI (Molecular Probes).
Fluorescent sporozoites were visualized using an upright fluorescence
microscope (Nikon Eclipse 90i).
Irradiated Sporozoite Immunization. For radiation-attenuated sporozoite
immunization, five 5-to-8 wk old C57BL/6 female mice were vaccinated i.v.
with 1 × 105 to 1.5 × 105 Pb/Pf sporozoites (see below) previously exposed to
20,000R in a γ irradiator. Mice received a total of three doses of irradiated
sporozoites separated by at least 2 wk. Before each dose, mice were bled,
and anti-CSP antibody levels were measured.
Sporozoite Challenge. Pb/Pf-infected A. stephensi mosquitoes provided by
the Johns Hopkins Malaria Research Institute Vector and Parasite Cores were
dissected in medium for isolation of salivary glands. Glands were spun down
at 7,000 rpm for 1 min at 4 °C, the pellet was ground in ∼100 μL of media to
break open the salivary glands, and the suspension was spun at 1,000 rpm
for 1 min at 4 °C. Supernatant was collected, and sporozoites were counted
using a hemocytometer. Mice were challenged by injection into the tail vein
with 1.0 × 104 to 2.0 × 104 transgenic Pb/Pf parasites. Approximately 40 h
later, mice were killed to assess parasite burden in livers. Whole livers were
homogenized in denaturing solution, and RNA was extracted as previously
described (35). After cDNA synthesis, parasite burdens were determined by
quantitative PCR for P. berghei 18S rRNA (25), and mouse GAPDH was used
as an internal control.
For the assessment of sterile protection, A. stephensi mosquitoes infected
with Pb/Pf parasites were starved overnight. Mice were anesthetized with
300–350 μL of 2% (wt/vol) Avertin and were individually subjected to
feeding from 10 or 15 mosquitoes for 5 min. The number of mosquitoes that
fed on each mouse, as indicated by the presence of blood in the midgut, was
recorded. Starting on day 4, blood was obtained from the cheek vein daily,
and smears were made. Smears were fixed with methanol for 30 s before
staining with a 10% Giemsa stain solution (Sigma) for 15 min and observed
under a microscope for blood-stage parasites. The day postinfection that
blood-stage parasitemia was evident was recorded. After confirmation of
parasitemia, mice were killed. Mice were considered to be sterilely protected
and were killed if there was no evidence of parasitemia by day 14.
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